179 related articles for article (PubMed ID: 33007530)
1. The human sialic acid-binding immunoglobulin-like lectin Siglec-9 and its murine homolog Siglec-E control osteoclast activity and bone resorption.
Andes FT; Adam S; Hahn M; Aust O; Frey S; Grueneboom A; Nitschke L; Schett G; Steffen U
Bone; 2021 Feb; 143():115665. PubMed ID: 33007530
[TBL] [Abstract][Full Text] [Related]
2. Sialic acid-binding immunoglobulin-like lectin 15 (Siglec-15) mediates periarticular bone loss, but not joint destruction, in murine antigen-induced arthritis.
Shimizu T; Takahata M; Kameda Y; Endo T; Hamano H; Hiratsuka S; Ota M; Iwasaki N
Bone; 2015 Oct; 79():65-70. PubMed ID: 26027508
[TBL] [Abstract][Full Text] [Related]
3. Impaired osteoclast differentiation and function and mild osteopetrosis development in Siglec-15-deficient mice.
Hiruma Y; Tsuda E; Maeda N; Okada A; Kabasawa N; Miyamoto M; Hattori H; Fukuda C
Bone; 2013 Mar; 53(1):87-93. PubMed ID: 23238125
[TBL] [Abstract][Full Text] [Related]
4. Anti-Siglec-15 antibody suppresses bone resorption by inhibiting osteoclast multinucleation without attenuating bone formation.
Tsukazaki H; Kikuta J; Ao T; Morimoto A; Fukuda C; Tsuda E; Minoshima M; Kikuchi K; Kaito T; Ishii M
Bone; 2021 Nov; 152():116095. PubMed ID: 34216837
[TBL] [Abstract][Full Text] [Related]
5. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
[TBL] [Abstract][Full Text] [Related]
6. Siglec-15 is a potential therapeutic target for postmenopausal osteoporosis.
Kameda Y; Takahata M; Mikuni S; Shimizu T; Hamano H; Angata T; Hatakeyama S; Kinjo M; Iwasaki N
Bone; 2015 Feb; 71():217-26. PubMed ID: 25460183
[TBL] [Abstract][Full Text] [Related]
7. Siglec-15, a member of the sialic acid-binding lectin, is a novel regulator for osteoclast differentiation.
Hiruma Y; Hirai T; Tsuda E
Biochem Biophys Res Commun; 2011 Jun; 409(3):424-9. PubMed ID: 21586272
[TBL] [Abstract][Full Text] [Related]
8. Siglec-15 on Osteoclasts Is Crucial for Bone Erosion in Serum-Transfer Arthritis.
Korn MA; Schmitt H; Angermüller S; Chambers D; Seeling M; Lux UT; Brey S; Royzman D; Brückner C; Popp V; Percivalle E; Bäuerle T; Zinser E; Winkler TH; Steinkasserer A; Nimmerjahn F; Nitschke L
J Immunol; 2020 Nov; 205(10):2595-2605. PubMed ID: 33020147
[TBL] [Abstract][Full Text] [Related]
9. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
Tsuda E; Fukuda C; Okada A; Karibe T; Hiruma Y; Takagi N; Isumi Y; Yamamoto T; Hasegawa T; Uehara S; Koide M; Udagawa N; Amizuka N; Kumakura S
Bone; 2022 Feb; 155():116241. PubMed ID: 34715394
[TBL] [Abstract][Full Text] [Related]
10. Isolation of a human homolog of osteoclast inhibitory lectin that inhibits the formation and function of osteoclasts.
Hu YS; Zhou H; Myers D; Quinn JM; Atkins GJ; Ly C; Gange C; Kartsogiannis V; Elliott J; Kostakis P; Zannettino AC; Cromer B; McKinstry WJ; Findlay DM; Gillespie MT; Ng KW
J Bone Miner Res; 2004 Jan; 19(1):89-99. PubMed ID: 14753741
[TBL] [Abstract][Full Text] [Related]
11. Mechanism and function of monoclonal antibodies targeting siglec-15 for therapeutic inhibition of osteoclastic bone resorption.
Stuible M; Moraitis A; Fortin A; Saragosa S; Kalbakji A; Filion M; Tremblay GB
J Biol Chem; 2014 Mar; 289(10):6498-6512. PubMed ID: 24446437
[TBL] [Abstract][Full Text] [Related]
12. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
13. Siglec-15-targeting therapy protects against glucocorticoid-induced osteoporosis of growing skeleton in juvenile rats.
Sato D; Takahata M; Ota M; Fukuda C; Hasegawa T; Yamamoto T; Amizuka N; Tsuda E; Okada A; Hiruma Y; Fujita R; Iwasaki N
Bone; 2020 Jun; 135():115331. PubMed ID: 32217159
[TBL] [Abstract][Full Text] [Related]
14. Involvement of Siglec-15 in regulating RAP1/RAC signaling in cytoskeletal remodeling in osteoclasts mediated by macrophage colony-stimulating factor.
Kobayashi H; Terkawi MA; Ota M; Hasegawa T; Yamamoto T; Shimizu T; Sato D; Fujita R; Murakami T; Amizuka N; Iwasaki N; Takahata M
Bone Res; 2024 Jun; 12(1):35. PubMed ID: 38849345
[TBL] [Abstract][Full Text] [Related]
15. Disruption of the sialic acid/Siglec-9 axis improves antibody-mediated neutrophil cytotoxicity towards tumor cells.
Lustig M; Chan C; Jansen JHM; Bräutigam M; Kölling MA; Gehlert CL; Baumann N; Mester S; Foss S; Andersen JT; Bastian L; Sondermann P; Peipp M; Burger R; Leusen JHW; Valerius T
Front Immunol; 2023; 14():1178817. PubMed ID: 37346044
[TBL] [Abstract][Full Text] [Related]
16. Deficiency in the phosphatase PHLPP1 suppresses osteoclast-mediated bone resorption and enhances bone formation in mice.
Mattson AM; Begun DL; Molstad DHH; Meyer MA; Oursler MJ; Westendorf JJ; Bradley EW
J Biol Chem; 2019 Aug; 294(31):11772-11784. PubMed ID: 31189651
[TBL] [Abstract][Full Text] [Related]
17. Engagement of sialylated glycans with Siglec receptors on suppressive myeloid cells inhibits anticancer immunity via CCL2.
Wieboldt R; Sandholzer M; Carlini E; Lin CW; Börsch A; Zingg A; Lardinois D; Herzig P; Don L; Zippelius A; Läubli H; Mantuano NR
Cell Mol Immunol; 2024 May; 21(5):495-509. PubMed ID: 38448555
[TBL] [Abstract][Full Text] [Related]
18. Molecular structure, expression, and the emerging role of Siglec-15 in skeletal biology and cancer.
Rashid S; Song D; Yuan J; Mullin BH; Xu J
J Cell Physiol; 2022 Mar; 237(3):1711-1719. PubMed ID: 34893976
[TBL] [Abstract][Full Text] [Related]
19. Siglec-15 as multifunctional molecule involved in osteoclast differentiation, cancer immunity and microbial infection.
Huang R; Zheng J; Shao Y; Zhu L; Yang T
Prog Biophys Mol Biol; 2023 Jan; 177():34-41. PubMed ID: 36265694
[TBL] [Abstract][Full Text] [Related]
20. Targeting Siglecs with a sialic acid-decorated nanoparticle abrogates inflammation.
Spence S; Greene MK; Fay F; Hams E; Saunders SP; Hamid U; Fitzgerald M; Beck J; Bains BK; Smyth P; Themistou E; Small DM; Schmid D; O'Kane CM; Fitzgerald DC; Abdelghany SM; Johnston JA; Fallon PG; Burrows JF; McAuley DF; Kissenpfennig A; Scott CJ
Sci Transl Med; 2015 Sep; 7(303):303ra140. PubMed ID: 26333936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
